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Protease-Activated Receptor-2: A Multifaceted Molecular 
Transducer in the Human Skin
Hjalte H. Andersen
Laboratory of Experimental Cutaneous Pain, SMI, Department of Health science and Technology, Faculty of Medicine, Aalborg University, 
Aalborg, Denmark
Dear Editor:
In the last issue of Annals of Dermatology, an exploratory 
study on the role of protease-activated peceptor-2 (PAR-2) 
in human skin was published by Shin et al.1. In consid-
eration of the assumed impact of PAR-2 in a variety of nor-
mal physiological processes as well as pathophysiological 
conditions2, this is considered a timely and contributive 
study. 
In the study, Shin et al.1 detected a high expression of 
PAR-2, particularly in the stratum granulosum of normal 
human skin, as well as in the acrosyringium of the eccrine 
sweat glands, while PAR-2 immunoreactivity was weak in 
the granular layer of the palmar epidermis. This is a highly 
interesting observation considering the established soma-
tosensory role of the PAR-2. In the skin, the PAR-family 
and PAR-2 in particular, is richly expressed on cutaneous 
primary sensory afferent nerve terminals known to convey 
the sensation of pruritus. These PAR-2-positive fibers are 
shown to be densely innervating the granular layer of 
non-glabrous skin. In a number of in vivo and human psy-
chophysical studies, PAR-2 and its co-effector transient re-
ceptor potential cation channel A1 (TRPA1) has been asso-
ciated with the non-histaminergic pruritic pathway where-
in superficial polymodal c-fibers transmits the sensation of 
itch in response to a number of chemical stimuli, includ-
ing mucunain, tryptase and the agonist applied in Shin et 
al.’s study1; SLIGRL-NH23. Activity in the non-hista-
minergic pathways of itch is thought to be a substantial 
contributor to the chronic itch associated with prevalent 
conditions such as atopic dermatitis and psoriasis, and the 
main reason that the itch accompanying with these con-
ditions respond poorly to antihistamines. Steinhoff et al.4 
(2003) have directly associated PAR-2-signalling with the 
occurrence of treatment resistant itch in atopic dermatitis 
and conclude that the receptor is likely to contribute to ex-
acerbate the ongoing inflammatory processes directly by 
pro-inflammation and indirectly by induction of scratching.
Additionally, Shin et al.1 found that human epidermal ker-
atinocytes (SV-HEKs), which were fully differentiated dis-
played significantly higher PAR-2 expression than un-
differentiated keratinocytes, which is in accordance with 
similar previous findings. This corresponds well with the 
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fact that both aforementioned skin conditions; atopic der-
matitis and psoriasis involves substantial epidermal hyper-
plasia5, in addition to PAR-2 associated sensory symp-
toms, most prominently itch, cutaneous inflammation and 
mild pain. 
It is unclear if PAR-2 is involved in the pathogenesis of 
inflammatory skin conditions or whether aberrations in 
PAR-2-signaling is a consequence of preceding etiological 
processes, which could be distinct between different path-
ophysiological conditions. However, PAR-2 does appear 
to play a significant role in skin physiology, inflammation 
and the related cutaneous sensory symptoms such as itch 
and pain. This makes the receptor an interesting pharma-
ceutical target for inflammatory skin diseases. 
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Betamethasone Butyrate Propionate Inhibits the Induction 
of Thymic Stromal Lymphopoietin in Cultured Normal 
Human Keratinocytes
Wei Zhang, Takashi Sakai, Yutaka Hatano, Sakuhei Fujiwara
Department of Dermatology, Faculty of Medicine, Oita University, Yufu, Japan
Dear Editor:
Thymic stromal lymphopoietin (TSLP), a key epithelial cell 
and keratinocyte-derived cytokine, has been shown to di-
rectly trigger allergic inflammation and the atopic march1,2. 
Therefore, suppression of TSLP expression should be a ra-
tional therapeutic strategy for allergic disorders such as 
atopic dermatitis (AD). In addition, topical treatments 
seem to be suitable for this strategy, since TSLP is pro-
duced in epithelia such as the epidermis. Topical gluco-
corticoid (GC) is the most popular treatment for AD and 
therefore, it is rational to examine the effects of GC on the 
expression of TSLP in keratinocytes. In fact, it has been 
shown that a GC, such as dexamethasone (Dex), but not 
calcineurin inhibitors, suppresses the expression of TSLP 
